Areas: ,

Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart

Mitochondrial aldehyde dehydrogenase 2 (ALDH2) was identified as an whose activation correlates with reduced ischemic heart damage in rodent models by Che-Hong Chen and colleagues from the Stanford University (USA), using an unbiased proteomic search. The research team wanted to find a that limits the severity of ischemia-induced cardiac damage occurring after a myocardial infarction or certain cardiac surgical procedures.

The scientists performed a high-throughput screen which led to a small-molecule activator of ALDH2 (Alda-1). When rats were treated with the substance before an ischemic event, the infarct size was decreased by 60%. Alda-1 has an inhibitory effect on the synthesis of cytotoxic aldehydes. This is is assumed to be the main activity of the .

In in vitro studies, Alda-1 showed exceptionally effective activation of ALDH2*2, an inactive form of ALDH2. The associated mutation occurs in 40% of East Asian patient cohorts.

The ALDH2 enhancer might be suitable for patients who are at risk of cardiac ischemia, such as during coronary bypass surgery.

Related antibodies on

Mitochondrial aldehyde dehydrogenase 2

Antibodies for the research area drugs:

Antibodies for the research area enzymes: